Showing 1 - 10 of 1,053
Persistent link: https://www.econbiz.de/10010495476
Prior studies suggest that consumer-directed health plans (CDHPs) -characterized by high deductibles and health care accounts- reduce health costs, but there is concern that enrollees indiscriminately reduce use of low-value services (e.g., unnecessary emergency department use) and high-value...
Persistent link: https://www.econbiz.de/10012457739
Prior studies suggest that consumer-directed health plans (CDHPs) -characterized by high deductibles and health care accounts- reduce health costs, but there is concern that enrollees indiscriminately reduce use of low-value services (e.g., unnecessary emergency department use) and high-value...
Persistent link: https://www.econbiz.de/10013028554
We investigate how formularies used by pharmacy benefit managers (PBMs) can affect manufacturer rebates for branded drugs. We first present a theoretical model of multidimensional contracting in which a PBM negotiates with drug manufacturers over menus of formulary-contingent rebate payments and...
Persistent link: https://www.econbiz.de/10015056114
Persistent link: https://www.econbiz.de/10010379568
Persistent link: https://www.econbiz.de/10014633598
Persistent link: https://www.econbiz.de/10014514601
Persistent link: https://www.econbiz.de/10013461821
Persistent link: https://www.econbiz.de/10014446859
We study the moral hazard effects of the drug copayment threshold in Finland using detailed prescription drug purchase data. The analysis reveals that the average drug costs increase discontinuously by 17% at the threshold above which out-of-pocket drug costs decrease substantially. Our results...
Persistent link: https://www.econbiz.de/10014289803